NEWS
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
Kineta has entered an exclusivity and right of first offer agreement with TuHURA Biosciences for its KVA12123 immuno-oncology drug program. Under the agreement, TuHURA has the exclusive right to negotiate the acquisition of Kineta's assets, patents, and development program related to KVA12123. This right is valid until October 1, 2024, with possible extension. Kineta will receive a nonrefundable $5 million payment from TuHURA. KVA12123, a VISTA blocking monoclonal antibody, is currently in Phase 1/2 clinical trials in the US for advanced solid tumors, showing good tolerance and no significant toxicities. Further data are expected in Q4 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7413Visitors
Follow